Labo’Life
Labo'Life is a privately-held European pharmaceutical group that develops and distributes micro-immunotherapy medicines — sublingual globules using low-dose cytokines and proprietary Specific Nucleic Acids (SNA®) — exclusively through pharmacies across ten European countries, serving prescribers, pharmacies, and patients with immune-related conditions.
- Company typePrivate
- Founded1992
- HeadquartersConsell, Spain
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Labo’Life does
Labo'Life is a privately-held European pharmaceutical group that develops, manufactures, and distributes micro-immunotherapy medicines — a therapeutic modality using low and ultra-low doses of cytokines (interleukins, interferons, chemokines, growth factors) and Specific Nucleic Acids (SNA®) to modulate immune responses. Founded in October–December 1992 by Christian Foissey with parallel establishments in western France and Consell (Mallorca), Spain, the group operates two GMP-compliant production facilities (Spain and Belgium, with the Belgian site operational since November 2004), an in-house R&D department created in 2007, and wholly-owned subsidiaries across Belgium, Spain, Italy, and France. Its commercial portfolio comprises five sublingual globule medicines authorized in Belgium: 2LEBV®, 2LHERP®, 2LPAPI® (prescription-only) and 2LVERU® and 2LVERU JUNIOR® (over-the-counter), plus the Laboratoires LORICA food-supplement line acquired in 2016.
The group's core technology rests on proprietary SNA® chemistry developed by Dr. Marichal in 1990-1992, delivered via a sublingual globule format that uses numbered capsules (1-10) to ensure sequential administration matching the natural chronology of immune responses. Labo'Life targets recurrent infections, allergies, inflammatory conditions, herpes virus reactivation, and autoimmune-related immune dysregulation. Customers are structured in three layers: healthcare professionals (doctors, therapists, pharmacists) who prescribe; an exclusive European pharmacy network that dispenses both Rx and OTC SKUs; and patients reached via pharmacy channels and dedicated educational blogs (misistemainmune.es, monsystemeimmunitaire.fr).
The business model is a pay-as-you-go, unit-box pharmaceutical sale (30-capsule packs, 3 blisters of 10) routed exclusively through pharmacies across ten European countries (Belgium, Spain, Italy, France, Germany, Austria, Switzerland, Portugal, Luxembourg, Netherlands). Go-to-market is dual-channel: enterprise field sales targeting prescribers through the med.labolife.com professional portal (vademecum, scientific publications, clinical trial information, online pharmacy ordering), and direct-to-consumer education via blogs and social media. The group operates without public listing, ticker, or disclosed funding rounds, sitting under the Spanish holding DIMI (Desarrollo Internacional de Micro-Inmunoterapia S.L.U.).
Labo’Life firmographics
Firmographics- Name
- Labo’Life
- Legal name
- DESARROLLO INTERNACIONAL DE MICRO-INMUNOTERAPIA S.L.U.
- Website
- https://labolife.com
- Company type
- Private
- Founded year
- 1992
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Labo'Life is a privately-held European pharmaceutical group that develops and distributes micro-immunotherapy medicines — sublingual globules using low-dose cytokines and proprietary Specific Nucleic Acids (SNA®) — exclusively through pharmacies across ten European countries, serving prescribers, pharmacies, and patients with immune-related conditions.
- Ownership category
- akta.pro rank
Labo’Life industry classification
Industry- Product category
- Micro-Immunotherapy Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)
- akta.pro secondary industries
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)
Keywords
Where Labo’Life is headquartered
LocationHeadquarters
- HQ city
- Consell
- HQ country
- Spain
- HQ region
- Europe
Offices4 records
Markets served
Labo’Life business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Pharmaceutical Medicines Sales: Sale of micro-immunotherapy medicines exclusively through pharmacies. Products include prescription-only medicines (2LEBV, 2LHERP, 2LPAPI) and over-the-counter medicines (2LVERU, 2LVERU JUNIOR). Medicines sold in 30-capsule boxes (3 blisters of 10 capsules each).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | Prescription medicines (Rx) |
| Other | Pay-as-you-go | Over-the-counter medicines (OTC) |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
Labo’Life product offering
Product offeringCore offering
Labo'Life develops, manufactures, and distributes micro-immunotherapy medicines that use low and ultra-low doses of immunologically active molecules (cytokines and Specific Nucleic Acids) to modulate the immune system. The portfolio consists of five main medicines (2LEBV, 2LHERP, 2LPAPI, 2LVERU, and 2LVERU JUNIOR) sold as sublingual globules in 30-capsule boxes, available both as prescription-only and over-the-counter products, distributed exclusively through pharmacies across European markets.
Product overview
Labo'Life is a pharmaceutical group and leader in micro-immunotherapy (low-dose immunotherapy). Their product portfolio centers on five main micro-immunotherapy medicines authorized in Belgium: 2LEBV®, 2LHERP®, 2LPAPI®, 2LVERU®, and 2LVERU JUNIOR® - all delivered as sublingual globules in 30-capsule packages. These sequential medicines use low and ultra-low doses of immunologically active molecules (cytokines including interleukins, interferons, chemokines, growth factors; and specific nucleic acids/SNA®) to modulate immune responses. The portfolio includes both prescription-only and over-the-counter formulations targeting different immune-related conditions. Labo'Life also provides healthcare professional resources through their dedicated portal (med.labolife.com), patient education materials, and public health blogs in multiple languages.
Differentiator
Problem solved
Functional benefit
Brands
- Labo'life: Primary brand name for micro-immunotherapy medicines and company operations across European markets.
Products and services
- 2LEBV
Quantifiable outcome
- Medicines help restore immune function balance in conditions where the immune system is involved
Companies that use Labo’Life
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
Labo’Life technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Labo’Life partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered minor and core.
- Laboratoires LORICAminorFood supplements manufacturer integrated into the Labo'Life group in March 2016 as part of the company's diversification strategy to offer solutions for maintaining and recovering health.
- BachiminorHealth organization mentioned in connection with FAGG compliance and Code of Good Practices for the pharmaceutical industry in Belgium.
- MeGeMIT (Medizinische Gesellschaft für Mikroimmuntherapie)coreMedical society dedicated to professional education in micro-immunotherapy in German-speaking countries.
- AEMI (Asociación Española de Microinmunoterapia)coreSpanish Association of Micro-Immunotherapy - professional society for training healthcare professionals in micro-immunotherapy.
- IFMi (Institut Français de Micro-immunothérapie)coreFrench Institute of Micro-Immunotherapy - professional society for training healthcare professionals in France.
- Specialized Healthcare Centers (Hospitals, Clinics, Private Practices)coreCollaboration with specialized healthcare centers for clinical studies - executing and coordinating interventional and non-interventional clinical studies. Collaboration with medical researchers and prescribers.
- Mallorca Integra Football SchoolminorAssociation providing handicap-appropriate football training programs for people with disabilities as part of social responsibility initiative 'Overcoming Barriers'.
- EducaClownminorNon-profit association creating clown theater performances to educate about immune system health in an engaging way.
- Conversaciones con Hipocrates PlatformminorExchange platform created to reflect on current healthcare challenges and promote a paradigm shift where the human is at the center.
- University of the Balearic Islands (UIB)minorCollaboration with UIB to promote youth employment and scientific knowledge acquisition. Sponsorship of Biology Olympiad and Mini Olympiad competitions.
Scale indicators6 records
Recent moves16 records
Expansion highlights6 records
Labo’Life competitors and assessment
Company assessmentDirect peers
- GUNA S.p.A. Italian pharmaceutical company specializing in low-dose medicine and biological regulatory therapy. Most directly comparable peer — same therapeutic modality (low-dose cytokines/SNA-adjacent biology), same pharmacy distribution model, and overlapping geographic presence in Italy/Europe.
- Biologische Heilmittel Heel GmbH: German manufacturer of low-dose, biologically-regulated medicines combining cytokines and homeopathic approaches. Closely comparable technology platform and therapeutic philosophy, with global distribution and similar prescriber/HCP targeting.
- Laboratoires Lehning: French pharmaceutical laboratory producing herbal and homeopathic medicines sold through pharmacies. Comparable pharmacy-channel specialty pharma model in France, with similar HCP-prescribed positioning, though focused on herbal/homeopathic rather than cytokine-based therapy.
Emerging players
- Wala Heilmittel GmbH: German manufacturer of anthroposophic/low-dose medicines and natural cosmetics with strong pharmacy distribution. Comparable philosophy in low-dose biologically-regulated therapy and similar European pharmacy-channel focus; smaller-scale than Labo'Life.
- Leti Pharma: Spanish specialty pharma focused on allergy immunotherapy and dermatology, distributed through pharmacies. Comparable European specialty pharma footprint, similar HCP-prescribing model, and overlapping focus on immune-related conditions though operating in conventional allergen immunotherapy.
Broad incumbents
- Stallergenes Greer: Global specialty immunology company focused on allergen immunotherapy (respiratory allergies, venom). Comparable as a specialty immunology pharma targeting HCPs and pharmacies, but operates in conventional allergen desensitization rather than micro-immunotherapy.
- Vifor Pharma: Swiss specialty pharma focused on iron deficiency, nephrology, and immunology-related therapies. Larger, publicly listed incumbent with broader conventional immunology portfolio and stronger commercial scale; overlapping HCP prescriber base in EU markets.
- Laboratoires Boiron: French global leader in homeopathic medicines, distributed primarily through pharmacies across Europe. Larger, publicly listed (Euronext), broader portfolio, and stronger brand but operates in an adjacent (homeopathic) rather than low-dose immunotherapy category — comparable channel and target HCPs.
- Sanofi (Specialty Care / Immunology): Global pharmaceutical incumbent with a large immunology and specialty care franchise (Dupixent, etc.). Not a direct competitor on low-dose immunotherapy but represents the dominant mainstream immunology option that prescribers may favor over niche micro-immunotherapy in core EU markets.
Regional players
- Laboratoires URGO: French specialty pharma focused on OTC consumer health, including immunity/wellness products sold through pharmacies. Comparable pharmacy-channel distribution and consumer health focus in core EU markets, though not in low-dose immunotherapy.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Labo’Life social profiles
Digital presenceLabo’Life compliance and trust
Trust signalCompliance4 records
Labo’Life financial estimates
Financial estimateRevenue estimate
Valuation estimate
Labo’Life leadership team
Management profileNumber of profiles
Labo’Life subsidiaries and ownership
Company hierarchySubsidiaries5 records
Labo’Life funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Labo’Life M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Labo’Life
What does Labo’Life do?
Labo'Life develops, manufactures, and distributes micro-immunotherapy medicines that use low and ultra-low doses of immunologically active molecules (cytokines and Specific Nucleic Acids) to modulate the immune system. The portfolio consists of five main medicines (2LEBV, 2LHERP, 2LPAPI, 2LVERU, and 2LVERU JUNIOR) sold as sublingual globules in 30-capsule boxes, available both as prescription-only and over-the-counter products, distributed exclusively through pharmacies across European markets.
Is Labo’Life a public or private company?
Labo’Life is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Labo’Life founded?
Labo’Life was founded in 1992. It employs 51 to 100 people.
Where is Labo’Life based?
Labo’Life is headquartered in Consell, Spain, in the Europe region.
How does Labo’Life make money?
One revenue line is on record: pharmaceutical Medicines Sales.
Who are Labo’Life's main competitors?
Direct peers on record are GUNA S.p.A., Biologische Heilmittel Heel GmbH and Laboratoires Lehning. Emerging players are Wala Heilmittel GmbH and Leti Pharma. Broad incumbents are Stallergenes Greer, Vifor Pharma, Laboratoires Boiron and Sanofi (Specialty Care / Immunology). Laboratoires URGO is listed as a regional player.
Does Labo’Life have an API?
No public API is recorded for Labo’Life.
What industry is Labo’Life in?
Labo’Life's product category is Micro-Immunotherapy Pharmaceuticals. Its primary akta.pro industry code is HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.